Aigle on for David Leveowitz's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for David Leveowitz at Citi inquired about the market opportunity in non-obstructive HCM and whether the sales force would need to be expanded to reach more community doctors for that launch.
Answer
Fady Malik, EVP of R&D, and Stuart Kupfer, SVP & Chief Medical Officer, described nHCM as a large, underdiagnosed population. Andrew Callos, EVP & Chief Commercial Officer, clarified that the initial physician target list is the same for both nHCM and oHCM, so no sales force expansion is anticipated at the nHCM launch.